RLAY Relay Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1812364 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY23.9%
TTM net income YoY1.3%
TTM EPS YoY12.8%
Revenue 3-yr CAGR-26.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,094.6%
Net margin-2,837.0%
FCF margin—
EBITDA margin-3,077.7%
Returns
ROE-41.2%
ROA-37.4%
ROIC (approx.)-41.8%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets9.2%
Debt / equity0.00x
Current ratio14.62x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $15.36M | $10.01M |
| R&D expense | $261.38M | $319.09M |
| SG&A expense | $56.71M | $76.59M |
| Operating income | -$302.74M | -$372.47M |
| Income tax | $0 | $0 |
| Net income | -$276.48M | -$337.71M |
| EBITDA | -$299.18M | -$367.00M |
| EPS (basic) | -1.61 | -2.36 |
| EPS (diluted) | -1.61 | -2.36 |
| Balance sheet | ||
| Cash & equivalents | $84.02M | $126.41M |
| Current assets | $578.28M | $809.20M |
| PP&E, net | $1.73M | $5.91M |
| Total assets | $621.33M | $871.30M |
| Current liabilities | $25.58M | $50.73M |
| Total liabilities | $54.27M | $93.50M |
| Shareholders' equity | $567.06M | $777.79M |
| Shares outstanding | 173.87M | 167.76M |
| Cash flow statement | ||
| Operating cash flow | -$235.46M | -$249.11M |
| Capital expenditure | $410,000 | $2.02M |
| Free cash flow | -$235.87M | -$251.12M |
| Investing cash flow | $192.80M | -$41.08M |
| Financing cash flow | $1.60M | $270.15M |
| Depreciation & amortization | $3.56M | $5.46M |
| Stock-based compensation | $62.42M | $94.14M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.